



ASX Announcement

18 May 2011

Appointment of Chief Financial Officer and Company Secretary

SYDNEY Australia, 18 May 2011: Sunshine Heart, Inc. (ASX: SHC), today announced the resignation of Ms Rowena Hubble as Chief Financial Officer and Company Secretary and the appointment of Mr Jeffrey Mathiesen to both positions effective 30 June 2011.

Sunshine Heart Chairman Mr Nick Callinan paid tribute to Ms Hubble for her significant contribution to the Company over the past years during which much progress has been made. The Board extends its thanks for her work and wishes her well in her future.

Mr Callinan said Mr Mathiesen has significant experience overseeing the international growth of a number of public and private high-growth technology companies. He is well qualified to manage Sunshine Heart's financial operations as for over 10 years he has served as CFO for several high-growth technology companies. He is also well qualified to manage the process for the Company's proposed listing on NASDAQ.

Mr Callinan welcomed Mr Mathiesen to the Company

Mr Mathiesen has more than two decades of experience in senior finance and operational management positions. Before joining Sunshine Heart, he was Vice President and CFO for Zareba Systems, Inc. (ZRBA), where he helped return the company to profitability and negotiated its sale at a premium.

Previously, As Vice President and CFO at Delphax Technologies, Inc. (DLPX), he oversaw cost reduction initiatives that helped return the company to profitability while directing the accounting and financial reporting functions for operations in the US, Canada, United Kingdom and France.

Mr Mathiesen will be based at the company's US headquarters in Minnesota. He is a certified public accountant who started his career at Deloitte & Touche, LLP, after completing a bachelor's of science in Accounting at the University of South Dakota.

About Sunshine Heart

Sunshine Heart (ASX: SHC) is a global medical device company committed to the commercialization of the C-Pulse® Heart Assist System, an implantable, non-blood contacting, heart assist therapy for the treatment of moderate to severe heart failure which can be implanted using a minimally invasive procedure. C-Pulse is designed to relieve the symptoms of heart failure through the use of counter-pulsation technology by enabling an increase in cardiac output, an increase in coronary blood flow, and a reduction in the heart's pumping load. The company has received approval from the U.S. Food and Drug Administration to conduct a U.S. feasibility clinical trial with the C-Pulse System. Sunshine Heart is a Delaware-based corporation headquartered in Minneapolis, MN, with a subsidiary presence in Australia. The company has been listed on the ASX since September 2004. For more information, please visit www.sunshineheart.com.

For more information please contact:

Dave Rosa
CEO Sunshine Heart
+ 1 (952) 345-4201
dave.rosa@sunshineheart.com

Andrew Geddes
CoActive Health Communications
+ 61 2 9555 4453 or 0408 677 734